Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922620 · ClinicalTrials.gov registry record · Phase 4
Liposomal Bupivacaine vs Peripheral Nerve Block
A Phase 4 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03922620 is a Phase 4 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 1 participants.
The verdict
NCT03922620, a Phase 4 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Liposomal bupivacaine has gained interest in recent literature for its potential to be an effective adjunct to other pain control modalities in a multi-modal approach to post-operative pain control. The goal of this investigation is to compare the efficacy of local administration of liposomal bupivacaine versus the efficacy of a peripheral nerve block in terms of post-operative pain scores after elective ankle and hindfoot surgery. The investigators hypothesize that there will not be a significant difference in the pain scores of these two groups in opioid naïve patients.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Peripheral Nerve Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922620
The ClinicalTrials.gov registry entry for NCT03922620 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT03922620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03922620 about?
NCT03922620 is a clinical study titled "Liposomal Bupivacaine vs Peripheral Nerve Block". Liposomal bupivacaine has gained interest in recent literature for its potential to be an effective adjunct to other pain control modalities in a multi-modal approach to post-operative pain control. The goal of this investigation is to compare the efficacy of local administration of liposomal bupiva...
What is the current status of trial NCT03922620?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2020-01-23. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03922620?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Peripheral Nerve Block (DRUG).
Who is sponsoring clinical trial NCT03922620?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.